Next Article in Journal
Lurasidone Sub-Chronically Activates Serotonergic Transmission via Desensitization of 5-HT1A and 5-HT7 Receptors in Dorsal Raphe Nucleus
Previous Article in Journal
Alternative Experimental Models for Studying Influenza Proteins, Host–Virus Interactions and Anti-Influenza Drugs
Previous Article in Special Issue
Measuring Daylight: A Review of Dosimetry in Daylight Photodynamic Therapy
Open AccessReview

The Dark Side: Photosensitizer Prodrugs

School of Pharmaceutical Sciences, University of Geneve, 1206 Geneva, Switzerland
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2019, 12(4), 148; https://doi.org/10.3390/ph12040148
Received: 14 August 2019 / Revised: 26 September 2019 / Accepted: 30 September 2019 / Published: 4 October 2019
(This article belongs to the Special Issue Photodynamic Therapy 2019)
Photodynamic therapy (PDT) and photodiagnosis (PD) are essential approaches in the field of biophotonics. Ideally, both modalities require the selective sensitization of the targeted disease in order to avoid undesired phenomena such as the destruction of healthy tissue, skin photosensitization, or mistaken diagnosis. To a large extent, the occurrence of these incidents can be attributed to “background” accumulation in non-target tissue. Therefore, an ideal photoactive compound should be optically silent in the absence of disease, but bright in its presence. Such requirements can be fulfilled using innovative prodrug strategies targeting disease-associated alterations. Here we will summarize the elaboration, characterization, and evaluation of approaches using polymeric photosensitizer prodrugs, nanoparticles, micelles, and porphysomes. Finally, we will discuss the use of 5-aminolevulinc acid and its derivatives that are selectively transformed in neoplastic cells into photoactive protoporphyrin IX.
Keywords: quenching; prodrugs; photodynamic therapy; 5-aminolevulinic acid quenching; prodrugs; photodynamic therapy; 5-aminolevulinic acid
MDPI and ACS Style

Sansaloni-Pastor, S.; Bouilloux, J.; Lange, N. The Dark Side: Photosensitizer Prodrugs. Pharmaceuticals 2019, 12, 148.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop